Developer docs
API playgroundTry for free, no card

Search company profiles

X9

Full company profile

uuid009ap4s

Namestring
X9
Legal namestring
X9, Inc.
Websiteurl
exploramed.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

X9, Inc. is a privately held medical device company founded in 2022 and incubated at ExploraMed in Mountain View, California, that is building an AI-guided point-of-care ultrasound ecosystem for minimally invasive diagnostics and procedural assistance. Its core technology combines real-time AI-powered ultrasound imaging with micro-level precision targeting procedures such as vascular access, biopsies, nerve blocks, and tumor ablations. The first commercialized product, an ultrasound-guided cannulation device intended to improve dialysis vascular access, received FDA clearance for its ultrasound-only version and completed a first-in-human feasibility study in November 2024; an enhanced power-assist version is in development. The company was launched in partnership with DaVita, a leading dialysis provider that invested through its venture group, anchoring X9's initial clinical validation and market entry into the dialysis segment. The platform is designed for interoperability with existing EMRs and hospital infrastructure, with built-in HIPAA and FDA 21 CFR Part 11 compliance architecture and a roadmap that includes predictive analytics and continuous AI health monitoring.

X9's business model centers on selling hardware devices into healthcare-provider workflows, with a broader ecosystem play encompassing software and services that support automated measurements, alerts, reporting, and reimbursement within existing payment structures. Pricing is not publicly disclosed and the company appears to use an enterprise field-sales motion targeting hospitals, dialysis providers, and multi-specialty care settings in the United States. Revenue is not yet disclosed and the company is best characterized as pre-commercial, with FDA clearance, feasibility study completion, and a December 2025 SEC Form D filing for an exempt offering of up to $33,000,708 USD (of which $8,568,181 has been sold) marking the transition from R&D toward early commercialization. Operating geographies are limited to the United States and the company remains at 1-10 employees under CEO Earl Bright.

Short descriptiontext

X9 is a medical device startup developing an AI-powered, point-of-care ultrasound platform with micro-precision for procedures including dialysis cannulation, vascular access, biopsies, and nerve blocks, serving healthcare providers and dialysis networks such as DaVita.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWallingford, United States
HQ citystring
Wallingford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI ultrasound imaging, medical devices, procedural guidance, point-of-care diagnostics, dialysis cannulation
Industry3 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Interventional Ultrasound Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Healthcare ecosystem platform (hardware, software, services)
TypeHardware Sales
Description

X9 is developing a comprehensive ecosystem including hardware devices, software platforms, and services designed for healthcare provider infrastructure. The platform supports timely, accurate reporting to facilitate reimbursement within existing payment structures.

exploramed.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

X9 is developing a scalable, single-handed, point-of-care ultrasound platform that combines real-time AI-powered imaging with micro-level precision to guide minimally invasive procedures such as vascular access, biopsies, nerve blocks, and tumor ablations. The platform integrates hardware, software, and services designed for interoperability with existing EMRs and hospital infrastructure, and includes an FDA-cleared ultrasound-guided cannulation device targeting dialysis patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First-in-human feasibility study completed November
Product overview1 text field

X9 is developing a comprehensive healthcare technology ecosystem consisting of hardware, software, and services built around a scalable, single-handed, point-of-care ultrasound platform. The core platform integrates real-time AI-powered ultrasound imaging with micro-level precision to support healthcare providers in performing vascular access, biopsies, nerve blocks, and tumor ablations. For the dialysis market specifically, X9 has developed an FDA-cleared ultrasound-guided cannulation device with a next-generation power-assist version in development. The ecosystem also includes an AI health monitoring system that enables continuous patient monitoring and predictive analytics. The platform is designed for interoperability with existing healthcare infrastructure including EMR systems, supporting automated measurements, alerts, and reporting.

Product and service2 records
1X9 Point-of-Care Ultrasound Platform
CategoryMedical Imaging Platform
Description

Scalable, single-handed, point-of-care ultrasound platform integrating real-time AI-powered imaging with micro-level precision to guide delicate procedures across multiple specialties and care settings. Engineered for EMR interoperability, automated measurements, alerts, predictive analytics, and HIPAA-compliant data handling for hospitals and healthcare providers.

2Ultrasound-Guided Cannulation Device
CategoryDialysis Vascular Access Device
Description

FDA-cleared ultrasound-guided medical device designed to improve the cannulation process for hemodialysis patients by reducing cannulation-related complications and costs while improving patient outcomes.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of handheld ultrasound devices with embedded AI for point-of-care imaging and procedural guidance. Direct competitor in AI-powered portable ultrasound for clinical workflows similar to X9's target use cases.

TypeBroad incumbent
Description

Global incumbent in medical imaging including ultrasound, with growing AI guidance capabilities (via Caption Health). Competes broadly across hospital imaging purchasing decisions that X9 must also win.

TypeBroad incumbent
Description

Global ultrasound and image-guided therapy vendor with AI-augmented imaging and integrated hospital IT. Sets competitive benchmarks for AI ultrasound and image-guided procedural capabilities X9 must match or beat.

TypeBroad incumbent
Description

Developer of interventional and procedural devices across vascular and adjacent therapy areas. Comparable as a procedural-focused medtech company expanding into image- and AI-guided therapy workflows.

TypeEmerging player
Description

Emerging player building robotic platforms for image-guided endovascular procedures. Comparable as a robotic procedural assistance peer whose trajectory informs adoption curves relevant to X9's power-assist roadmap.

6Caption Health (acquired by GE HealthCare)
TypeDirect peer
Description

AI software for real-time ultrasound guidance that automates image acquisition and diagnostic-quality assessment. Highly comparable as an AI-navigation overlay for ultrasound-based procedures, now distributed via GE HealthCare.

TypeBroad incumbent
Description

Large medical imaging incumbent offering ultrasound systems integrated with enterprise imaging/EMR workflows. Competes for hospital capital budgets and AI-imaging mindshare relevant to X9's enterprise sales motion.

TypeDirect peer
Description

Handheld, AI-enabled point-of-care ultrasound platform targeting multi-specialty and bedside use. Closest direct competitor to X9's single-handed AI-ultrasound procedural guidance model across vascular access and procedural applications.

TypeBroad incumbent
Description

Major manufacturer of vascular access devices and ultrasound-guided cannulation tools (e.g., Site-Rite). Directly relevant to X9's anchor dialysis cannulation use case and competing procurement relationships in dialysis centers.

TypeBroad incumbent
Description

Portfolio of vascular access, Arrow, and procedural guidance products including ultrasound-assisted cannulation devices. Comparable competitive set for X9's anchor vascular access indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

X9

Interventional Ultrasound Medical Devicesexploramed.com

X9 is a medical device startup developing an AI-powered, point-of-care ultrasound platform with micro-precision for procedures including dialysis cannulation, vascular access, biopsies, and nerve blocks, serving healthcare providers and dialysis networks such as DaVita.

What X9 does

X9, Inc. is a privately held medical device company founded in 2022 and incubated at ExploraMed in Mountain View, California, that is building an AI-guided point-of-care ultrasound ecosystem for minimally invasive diagnostics and procedural assistance. Its core technology combines real-time AI-powered ultrasound imaging with micro-level precision targeting procedures such as vascular access, biopsies, nerve blocks, and tumor ablations. The first commercialized product, an ultrasound-guided cannulation device intended to improve dialysis vascular access, received FDA clearance for its ultrasound-only version and completed a first-in-human feasibility study in November 2024; an enhanced power-assist version is in development. The company was launched in partnership with DaVita, a leading dialysis provider that invested through its venture group, anchoring X9's initial clinical validation and market entry into the dialysis segment. The platform is designed for interoperability with existing EMRs and hospital infrastructure, with built-in HIPAA and FDA 21 CFR Part 11 compliance architecture and a roadmap that includes predictive analytics and continuous AI health monitoring.

X9's business model centers on selling hardware devices into healthcare-provider workflows, with a broader ecosystem play encompassing software and services that support automated measurements, alerts, reporting, and reimbursement within existing payment structures. Pricing is not publicly disclosed and the company appears to use an enterprise field-sales motion targeting hospitals, dialysis providers, and multi-specialty care settings in the United States. Revenue is not yet disclosed and the company is best characterized as pre-commercial, with FDA clearance, feasibility study completion, and a December 2025 SEC Form D filing for an exempt offering of up to $33,000,708 USD (of which $8,568,181 has been sold) marking the transition from R&D toward early commercialization. Operating geographies are limited to the United States and the company remains at 1-10 employees under CEO Earl Bright.

X9 firmographics

Firmographics
Name
X9
Legal name
X9, Inc.
Website
https://exploramed.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
X9 is a medical device startup developing an AI-powered, point-of-care ultrasound platform with micro-precision for procedures including dialysis cannulation, vascular access, biopsies, and nerve blocks, serving healthcare providers and dialysis networks such as DaVita.
Ownership category
akta.pro rank

X9 industry classification

Industry
Product category
Interventional Ultrasound Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • AI ultrasound imaging
  • Medical devices
  • Procedural guidance
  • Point-of-care diagnostics
  • Dialysis cannulation

Where X9 is headquartered

Location

Headquarters

HQ city
Wallingford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

X9 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Healthcare ecosystem platform (hardware, software, services): X9 is developing a comprehensive ecosystem including hardware devices, software platforms, and services designed for healthcare provider infrastructure. The platform supports timely, accurate reporting to facilitate reimbursement within existing payment structures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

X9 product offering

Product offering

Core offering

X9 is developing a scalable, single-handed, point-of-care ultrasound platform that combines real-time AI-powered imaging with micro-level precision to guide minimally invasive procedures such as vascular access, biopsies, nerve blocks, and tumor ablations. The platform integrates hardware, software, and services designed for interoperability with existing EMRs and hospital infrastructure, and includes an FDA-cleared ultrasound-guided cannulation device targeting dialysis patients.

Product overview

X9 is developing a comprehensive healthcare technology ecosystem consisting of hardware, software, and services built around a scalable, single-handed, point-of-care ultrasound platform. The core platform integrates real-time AI-powered ultrasound imaging with micro-level precision to support healthcare providers in performing vascular access, biopsies, nerve blocks, and tumor ablations. For the dialysis market specifically, X9 has developed an FDA-cleared ultrasound-guided cannulation device with a next-generation power-assist version in development. The ecosystem also includes an AI health monitoring system that enables continuous patient monitoring and predictive analytics. The platform is designed for interoperability with existing healthcare infrastructure including EMR systems, supporting automated measurements, alerts, and reporting.

Differentiator

Problem solved

Functional benefit

Products and services

  • X9 Point-of-Care Ultrasound Platform Scalable, single-handed, point-of-care ultrasound platform integrating real-time AI-powered imaging with micro-level precision to guide delicate procedures across multiple specialties and care settings. Engineered for EMR interoperability, automated measurements, alerts, predictive analytics, and HIPAA-compliant data handling for hospitals and healthcare providers.
  • Ultrasound-Guided Cannulation Device FDA-cleared ultrasound-guided medical device designed to improve the cannulation process for hemodialysis patients by reducing cannulation-related complications and costs while improving patient outcomes.

Quantifiable outcome

  • First-in-human feasibility study completed November

Companies that use X9

Customer profile

Segments2 records

Ideal customer profiles2 records

X9 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

X9 partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

X9 competitors and assessment

Company assessment

Direct peers

  • Exo: Developer of handheld ultrasound devices with embedded AI for point-of-care imaging and procedural guidance. Direct competitor in AI-powered portable ultrasound for clinical workflows similar to X9's target use cases.
  • Caption Health (acquired by GE HealthCare): AI software for real-time ultrasound guidance that automates image acquisition and diagnostic-quality assessment. Highly comparable as an AI-navigation overlay for ultrasound-based procedures, now distributed via GE HealthCare.
  • Butterfly Network: Handheld, AI-enabled point-of-care ultrasound platform targeting multi-specialty and bedside use. Closest direct competitor to X9's single-handed AI-ultrasound procedural guidance model across vascular access and procedural applications.

Broad incumbents

  • GE HealthCare: Global incumbent in medical imaging including ultrasound, with growing AI guidance capabilities (via Caption Health). Competes broadly across hospital imaging purchasing decisions that X9 must also win.
  • Siemens Healthineers: Global ultrasound and image-guided therapy vendor with AI-augmented imaging and integrated hospital IT. Sets competitive benchmarks for AI ultrasound and image-guided procedural capabilities X9 must match or beat.
  • Penumbra: Developer of interventional and procedural devices across vascular and adjacent therapy areas. Comparable as a procedural-focused medtech company expanding into image- and AI-guided therapy workflows.
  • Philips: Large medical imaging incumbent offering ultrasound systems integrated with enterprise imaging/EMR workflows. Competes for hospital capital budgets and AI-imaging mindshare relevant to X9's enterprise sales motion.
  • Becton, Dickinson and Company (BD) — Vascular Access: Major manufacturer of vascular access devices and ultrasound-guided cannulation tools (e.g., Site-Rite). Directly relevant to X9's anchor dialysis cannulation use case and competing procurement relationships in dialysis centers.
  • Teleflex: Portfolio of vascular access, Arrow, and procedural guidance products including ultrasound-assisted cannulation devices. Comparable competitive set for X9's anchor vascular access indication.

Emerging players

  • Robocath: Emerging player building robotic platforms for image-guided endovascular procedures. Comparable as a robotic procedural assistance peer whose trajectory informs adoption curves relevant to X9's power-assist roadmap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

X9 compliance and trust

Trust signal

Compliance2 records

X9 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

X9 leadership team

Management profile

Number of profiles

Profiles1 record

X9 funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

X9 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about X9

What does X9 do?

X9 is developing a scalable, single-handed, point-of-care ultrasound platform that combines real-time AI-powered imaging with micro-level precision to guide minimally invasive procedures such as vascular access, biopsies, nerve blocks, and tumor ablations. The platform integrates hardware, software, and services designed for interoperability with existing EMRs and hospital infrastructure, and includes an FDA-cleared ultrasound-guided cannulation device targeting dialysis patients.

Is X9 a public or private company?

X9 is a private company. It is classified as venture growth investor backed and is currently operating.

When was X9 founded?

X9 was founded in 2022. It employs 1 to 10 people.

Where is X9 based?

X9 is headquartered in Wallingford, United States, in the North America region.

How does X9 make money?

One revenue line is on record: healthcare ecosystem platform (hardware, software, services).

Who are X9's main competitors?

Direct peers on record are Exo, Caption Health (acquired by GE HealthCare) and Butterfly Network. Broad incumbents are GE HealthCare, Siemens Healthineers, Penumbra, Philips, Becton, Dickinson and Company (BD) — Vascular Access and Teleflex. Robocath is listed as an emerging player.

Does X9 have an API?

No public API is recorded for X9.

What industry is X9 in?

X9's product category is Interventional Ultrasound Medical Devices. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageX9 Receives FDA Breakthrough Device Designation for Investigational Dialysis Cannulation System and Completes Second Clinical StudyX9, Inc. received FDA Breakthrough Device Designation for its investigational ultrasound system with power-assisted needle insertion for hemodialysis cannulation. The company also completed ACCESS-2, a study of ten patients, which showed successful needle placement and no serious device-related adverse events. X9 plans to continue clinical development.GlobeNewswireX9 Receives FDA Breakthrough Device Designation for Investigational Dialysis Cannulation System and Completes Second Clinical StudyX9, Inc. announced the FDA granted Breakthrough Device Designation to its X9 Ultrasound System with Power-Assisted Needle Insertion for hemodialysis cannulation. The company also completed ACCESS-2, a study of ten patients, which showed successful needle placement and no serious device-related adverse events. The designation does not constitute FDA clearance or approval.MedTech DiveDialysis cannulation can be difficult. A startup is working to improve it.X9, a startup launched from medical device incubator ExploraMed through a partnership with dialysis provider DaVita, is developing an ultrasound-guided device to improve the cannulation process for dialysis patients. The company has already received FDA clearance for its ultrasound-only version and completed a first-in-human feasibility study in November, with plans to pursue authorization for an enhanced version with power-assist capability. DaVita invested in X9 through its venture group, with the goal of reducing cannulation-related complications and costs while improving patient outcomes.